This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Aragon Pharmaceuticals, Inc.. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Innovations by Peter Hellemans in Prostate Cancer Treatment
Introduction
Peter Hellemans is a notable inventor based in Beerse, Belgium. He has made significant contributions to the field of medicine, particularly in the treatment of prostate cancer. His innovative work focuses on developing effective therapies for patients with severe hepatic impairment.
Latest Patents
Peter Hellemans holds a patent for "Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment." This patent describes methods of treating non-metastatic castration-resistant prostate cancer using androgen receptor inhibitors, including a specific compound: 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. This innovation represents a significant advancement in cancer treatment options.
Career Highlights
Peter Hellemans is associated with Aragon Pharmaceuticals, Inc., where he continues to work on groundbreaking research and development in oncology. His expertise and dedication to improving patient outcomes have made him a valuable asset in the pharmaceutical industry.
Collaborations
Peter has collaborated with talented professionals in his field, including Caly Chien and Alex Yu. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to the development of effective treatments.
Conclusion
Peter Hellemans is a distinguished inventor whose work in androgen receptor inhibitors has the potential to transform the treatment landscape for prostate cancer patients with severe hepatic impairment. His contributions to medical science are noteworthy and continue to inspire advancements in cancer therapy.